Sakari Hietanen
sakari.hietanen@utu.fi |
- Deciphering cancer genomes with GenomeSpy : a grammar-based visualization toolkit (2024)
- GigaScience
- Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer : Results from the PRIMA/ENGOT-OV26/GOG-3012 trial (2024)
- Gynecologic Oncology
- Extensive mutational ctDNA profiles reflect High-grade serous cancer tumors and reveal emerging mutations at recurrence (2024)
- Translational Oncology
- (2024)
- BMC CancerEJSO - European Journal of Surgical Oncology
- HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma (2024)
- Gynecologic Oncology
- Is it safe to operate selected low-risk endometrial cancer patients in secondary hospitals? (2024)
- Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations (2024)
- JAMA Network Open
- Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial (2024)
- International Journal of Gynecological Cancer
- Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors (2024)
- Journal of Clinical Oncology
- Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study (2024)
- Acta Oncologica



